{"id":13569,"date":"2013-05-20T00:00:45","date_gmt":"2013-05-19T22:00:45","guid":{"rendered":"http:\/\/alcyon:7777\/transgene170914\/?p=13569"},"modified":"2025-11-12T16:40:57","modified_gmt":"2025-11-12T15:40:57","slug":"phase-ii-trial-of-pexa-vec-pexastimogene-devacirepvec-jx-594-an-oncolytic-and-immunotherapeutic-vaccinia-virus-followed-by-sorafenib-in-patients-with-advanced-hepatocellular-carcinoma-hcc-2","status":"publish","type":"post","link":"https:\/\/www.transgene.com\/fr\/phase-ii-trial-of-pexa-vec-pexastimogene-devacirepvec-jx-594-an-oncolytic-and-immunotherapeutic-vaccinia-virus-followed-by-sorafenib-in-patients-with-advanced-hepatocellular-carcinoma-hcc-2\/","title":{"rendered":"Phase II trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, followed by sorafenib in patients with advanced hepatocellular carcinoma (HCC)"},"content":{"rendered":"<p><a href=\"http:\/\/meeting.ascopubs.org\/cgi\/content\/abstract\/31\/15_suppl\/4122?sid=e16b8da1-8ce1-4b77-8ecd-372140abfe94\">link<br \/>\n<\/a>J. Heo, C. Breitbach, M. Cho, T.H. Hwang, C.W. Kim, U.B. Jeon, H.Y. Woo, K.T. Yoon, J.W. Lee, J. Burke, T. Hickman, K. Dubois, L. Longpre, R. Patt, D.H. Kirn<br \/>\n<em>Journal of clinical Oncology, 2013, 31, (suppl; abstr 4122)<\/em><br \/>\n<span style=\"display:block\">[Publication]<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>link J. Heo, C. Breitbach, M. Cho, T.H. Hwang, C.W. Kim, U.B. Jeon, H.Y. Woo, K.T. Yoon, J.W. Lee, J. Burke, T. Hickman, K. Dubois, L. Longpre, R. Patt, D.H. Kirn Journal of clinical Oncology, 2013, 31, (suppl; abstr 4122) [Publication]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_coblocks_attr":"","_coblocks_dimensions":"","_coblocks_responsive_height":"","_coblocks_accordion_ie_support":"","_uag_custom_page_level_css":"","footnotes":""},"categories":[181,148,5],"tags":[],"class_list":["post-13569","post","type-post","status-publish","format-standard","hentry","category-other-fr","category-148","category-publication-fr","entry"],"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"post-thumbnail":false},"uagb_author_info":{"display_name":"alcyon","author_link":"https:\/\/www.transgene.com\/fr\/author\/alcyon\/"},"uagb_comment_info":0,"uagb_excerpt":"link J. Heo, C. Breitbach, M. Cho, T.H. Hwang, C.W. Kim, U.B. Jeon, H.Y. Woo, K.T. Yoon, J.W. Lee, J. Burke, T. Hickman, K. Dubois, L. Longpre, R. Patt, D.H. Kirn Journal of clinical Oncology, 2013, 31, (suppl; abstr 4122) [Publication]","_links":{"self":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/posts\/13569","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/comments?post=13569"}],"version-history":[{"count":1,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/posts\/13569\/revisions"}],"predecessor-version":[{"id":38826,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/posts\/13569\/revisions\/38826"}],"wp:attachment":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/media?parent=13569"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/categories?post=13569"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/tags?post=13569"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}